NSF: History, Diagnosis, and the Registry
Transcript of NSF: History, Diagnosis, and the Registry
![Page 1: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/1.jpg)
Nephrogenic Systemic Fibrosis
History, Diagnosis & The Registry
Shawn E. Cowper, MD
Associate Professor of Dermatology and Pathology
Yale University
New Haven, CT
![Page 2: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/2.jpg)
January 1997
![Page 3: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/3.jpg)
![Page 4: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/4.jpg)
![Page 5: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/5.jpg)
Philip LeBoit, MD
![Page 6: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/6.jpg)
AJDP, October 2001
![Page 7: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/7.jpg)
Pink Plaques Superficial Dermal Involvement
![Page 8: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/8.jpg)
Reticulated Lesions Superficial Dermal Involvement
![Page 9: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/9.jpg)
Severe Contractures Ankles and toes locked
![Page 10: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/10.jpg)
Deep Involvement Severe Contractures
![Page 11: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/11.jpg)
Registry population characteristics (n=345)
![Page 12: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/12.jpg)
Age at NSF onset, Registry cases
![Page 13: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/13.jpg)
Renal status at NSF onset, Registry
Dialysis (79%)Hemodialysis (52%)Peritoneal Dialysis (16%)End Stage Renal Disease (11%)
Non-Dialysis (17%)Acute Kidney Injury (10%)Renal Insufficiency (8%)
Stage IV CKD (1.5%)Stage V CKD (3%)
Post-Transplant (3%)
![Page 14: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/14.jpg)
2003
![Page 15: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/15.jpg)
JAAD, January 2003
•
Scleral plaques in NFD patients
![Page 16: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/16.jpg)
![Page 17: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/17.jpg)
Archives of Dermatology, July 2003
•
Known history of anti-
thrombin III and Factor II deficiency
•
Patient elected to discontinue dialysis due to intolerable morbidity
•
Findings included fibrosis of proximal esophagus, diaphragm, and psoas
muscle
![Page 18: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/18.jpg)
Involved skeletal muscle tissue from a patient with NSF
![Page 19: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/19.jpg)
Involved cardiac (heart) muscle from a deceased NSF patient
![Page 20: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/20.jpg)
Involved cardiac (heart) muscle from a deceased NSF patient
![Page 21: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/21.jpg)
AJDP, August 2003
![Page 22: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/22.jpg)
Tissue localized fibrocytes in NSF (red=procollagen I/brown=CD34)
![Page 23: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/23.jpg)
Current Opinion in Rheumatology, October 2003
![Page 24: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/24.jpg)
Thrombosis and Surgery
What do these have in common?
![Page 25: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/25.jpg)
2005
![Page 26: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/26.jpg)
Nephrology Dialysis Transplantation, January 2006
First published association of NSF with gadolinium administration
![Page 27: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/27.jpg)
![Page 28: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/28.jpg)
Strength of Association, Presence and Magnitude
J Am Acad Dermatol. 2007 Jan;56(1):21-6. Epub
2006 Nov 9
J Am Acad Dermatol. 2007 Jan;56(1):27-30. Epub
2006 Nov 15
![Page 29: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/29.jpg)
Gadolinium particles in NSF tissue
![Page 30: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/30.jpg)
Temporal: NSF latency
n
Weeks post Gd exposure before symptom onset
![Page 31: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/31.jpg)
GBCA dose/exposure, Registry cases (n=78)
![Page 32: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/32.jpg)
Animal and ex-vivo tests
J. Pathol. Vol.214, 5 Pages: 584-593
Courtesy Bayer-Schering Pharma
![Page 33: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/33.jpg)
Nephrogenic Systemic Fibrosis
Clinical Scoring
![Page 34: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/34.jpg)
NSF -
Major Criterion
Patterned Plaques
Red to violaceous, hyperpigmented, thin plaques showing polygonal to reticular morphologies on the upper extremities
![Page 35: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/35.jpg)
NSF -
Major Criterion
Joint contractures
Often with edema of the fingers and wrists, toes and ankles [absence of signs of scleroderma]. Loss of range of motion of
fingers, wrists, elbows
![Page 36: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/36.jpg)
NSF -
Major Criterion
“Cobblestoning”
Deep induration showing a pattern of bumpiness over the upper arms and/or thighs
![Page 37: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/37.jpg)
NSF -
Major Criterion
Marked Induration/Peau d’orange
Unpinchable, firm, shiny, often hyperpigmented bound down skin over extremities. Peau d’orange dimpling
![Page 38: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/38.jpg)
NSF -
Minor Criterion
Puckering/Linear Banding
Focal areas/linear bands of bound-down skin on an upper extremity or proximal lower extremity (thigh)
![Page 39: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/39.jpg)
NSF -
Minor Criterion
Superficial NSF
Hyperpigmented, pink or flesh colored macules
coalescing into patches or thin plaques on the upper extremities (common) or trunk (rare).
May have epidermal change (fine scale)
![Page 40: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/40.jpg)
NSF -
Minor Criterion
Dermal Papules
Subtle, flesh-colored papules without epidermal changes
![Page 41: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/41.jpg)
NSF -
Minor Criterion
Scleral
Plaques
Patient < 45 years old
![Page 42: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/42.jpg)
Clinical Scoring
•
Major Criteria
–
Patterned Plaques
–
Joint Contractures
–
Cobblestoning
–
Marked Induration/Peau d’orange (upper extremity or above knee)
•
Minor Criteria
–
Puckering/Linear Banding
–
Superficial (Plaque/Patch)
–
Dermal Papules
–
Scleral plaques (pt <45 yo)
•
Scoring
–
> 1 Major Criterion Highly Consistent = 4
–
1 Major Criterion Consistent = 3
–
> 1 Minor Criterion Suggestive = 2
–
0-1 Criterion
Inconsistent = 1
–
Another Diagnosis
Excluded = 0
![Page 43: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/43.jpg)
Nephrogenic Systemic Fibrosis
Pathological Scoring
![Page 44: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/44.jpg)
![Page 45: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/45.jpg)
Increased Dermal Cellularity
![Page 46: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/46.jpg)
CD34+
![Page 47: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/47.jpg)
CD34+ (“Tram-Tracks”)
![Page 48: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/48.jpg)
Thick and Thin Collagen Fibers
![Page 49: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/49.jpg)
Preserved Elastic
![Page 50: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/50.jpg)
Septal
Involvement
![Page 51: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/51.jpg)
“Lollipop”
Sign
![Page 52: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/52.jpg)
![Page 53: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/53.jpg)
![Page 54: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/54.jpg)
Pathology Scoring
•
Increased Cellularity (+1)
•
CD34+ Tram-tracks
(+1)
•
Thick and thin collagen fibers
(+1)
•
Elastic preservation (-1 if elastic absent)
•
Septal involvement
(+1)
•
Lollipop Sign
(+3)
•
Highly Consistent (Score = 4 or 5)
•
Consistent (Score = 3)
•
Suggestive (Score = 2)
•
Inconsistent (Score = 1)
•
Excluded (Score = 0)
![Page 55: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/55.jpg)
Diagnostic Grid
![Page 56: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/56.jpg)
Nephrogenic Systemic Fibrosis
The Registry and the Future
![Page 57: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/57.jpg)
NSF Registry case sources
![Page 58: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/58.jpg)
US Distribution of Registry cases (n=320)
![Page 59: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/59.jpg)
Patient impact, Registry data (n=345)
![Page 60: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/60.jpg)
NSF onset dates, Registry cases Cumulative
n
Calendar Year
< 304
![Page 61: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/61.jpg)
![Page 62: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/62.jpg)
Temporal association with NSF onset (n=78)
![Page 63: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/63.jpg)
International Center for NSF Research
Supported by a grant from the General Clinical Research Center at Yale
http://www.icnsfr.org
Yale University
Carol Hribko
(Registry Coordinator)
Ali Abu-Alfa, MD (Nephrology) Richard Bucala, MD PhD (Rheumatology)
Richard Edelson, MD (Dermatology)Michael Girardi, MD (Dermatology)
Avery LaChance
(Research Assistant)Mark Perazella, MD (Nephrology)Jeffrey Weinreb, MD (Radiology)
Additional thanks…
Philip Boyer, MD PhD (U Colorado)Dirk Elston, MD (Geisinger
MC, PA) Whitney High, MD (U Colorado)
Emanuel Kanal, MD (U Pittsburgh)Ira Krefting, MD (US FDA)
Phillip Kuo, MD PhD (U Arizona)Philip E. Leboit, MD (UCSF)
Sameh
Morcos
(Sheffield, UK)Priti
Patel, MD (CDC&P, Atlanta)Georges Saab, MD (U Missouri)Lyndon Su, MD (U Michigan)
Jonathan Kay, MD (U Massachusetts)Charles Bennett, MD PhD (Northwestern U)
And the many patients, family, physicians, attorneys and friends
who have been instrumental in bringing this work together!
![Page 64: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/64.jpg)
Use of GBCAs in Clinical Practice• Purpose
– Provide background concerning use of GBCAs in day to day practice and the possible implications of any limitations of their use
• Outline– Clinical Utility– Current Practice– Impact on Patients
![Page 65: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/65.jpg)
Use of GBCAs in Clinical Practice• Clinical Utility
– Improve • detection (sensitivity)• characterization (specificity)
– Disruption of “blood-brain barrier”
• staging (margins, number)• confidence level• reliability & exam time (eg. MRA)
Without GBCA
With GBCA
![Page 66: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/66.jpg)
GBCA-enhanced MRI plays an essential role in modern medical diagnosis
![Page 67: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/67.jpg)
• None are FDA approved for use in the;– Heart– Breast– Musculoskeletal System– Intra-articular or intra-arterial
• Only one is approved for CE-MRA (AIOD only) – >1,000,000 GBCA-MRA procedures are performed
each year using GBCAs not approved for MRA• All not approved for higher doses, faster
injection rates, or pediatric patients
“Off-label” use of GBCAs has been common
![Page 68: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/68.jpg)
MRI Scans in the US
0
5000
10000
15000
20000
25000
30000
35000
40000
1999 2001 2003 2005 2007
Scans (000's)G BCA (000's)
25% 25% 26% 26% 27% 28% 28% 28% 28% 29%
% Scans with GBCA
Source: Arlington Medical Research (AMR)
![Page 69: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/69.jpg)
GBCA Utilization39% Brain/Brain Stem
20% Spinal Canal & Contents
13% Angiography (MRA)
4% Face/Orbit/Neck
5% Abdomen (complete)
3% Pelvis
3% Other
10% Extremities
2% Breast
Source: Arlington Medical Research (AMR)
![Page 70: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/70.jpg)
MRA Magnetic Resonance Angiography
= MRI of Blood VesselsMagnetic Resonance Imaging
MRI Magnetic Resonance Imaging
![Page 71: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/71.jpg)
1993
2009
1994
Non-CE-MRA
“High dose” CE-MRA
Non-CE-MRA
MRAMagnetic Resonance Angiography
![Page 72: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/72.jpg)
GBCA-MRA Procedures and GBCA Volume
0
200
400
600
800
1000
1200
1400
1999 2001 2003 2005 2007
CE-M RA (000's)Volume (cc's)
23 22 23 24 25 26 28 27 25 24Average GBCA Volume Per CE-MRA Procedure (ml/procedure)
Source: Arlington Medical Research (AMR)
![Page 73: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/73.jpg)
Prior to link with NSF, GBCAs were commonly (and often preferentially) used in patients with renal insufficiency because they are less likely to harm the kidneys than iodinated contrast agents used for CT
Contrast-induced Nephropathy (CIN/CIAKI)
Rofsky NM, et al. Radiology 1991;180:85–89.Haustein J, et al. Invest Radiol 1992;27:153–156.Niendorf HP, et al. Invest Radiol 1994;29(suppl 2):S179–S182.Prince MR, et al. Radiology 1996;6:162–166.
Thomsen HS. Eur Radiol 2004;14:1654–1656.Thomsen HS. AJR 2003;181:1463–1471.Elmståhl B, et al. Acad Radiol 2004;11:1219–1228.Gemery J, et al. AJR 1998;171:1277–1278.Nyman U, et al. Radiology 2002;223:311–318.
![Page 74: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/74.jpg)
Adverse Events• The majority of AEs resulting from both iodinated agent and
GBCA exposure are mild• More common with iodinated agents
– 0.15–0.7% with iodinated agents– 0.03%–0.2% with GBCAsExamples:
Among 456,930 contrast doses, AEs occurred in 0.15% with low-osmolar iodinated agent vs 0.04% with GBCA
In a pediatric population, 0.18% incidence of acute allergic-like reaction to low- osmolality nonionic iodinated contrast compared with 0.04% with GBCAs
Among 78,353 GBCA injections, acute allergic-like reactions occurred in 0.07%, of which 19% were moderate and 7% severe
Murphy KP, et al. Acad Radiol 1999;6:656–664.Li A, et al. Br J Radiol 2006;79:368–337.Jordan RM, Mintz RD. AJR 1995;164:743–744.
Mortelé KJ, et al. AJR 2005;184:31–34.Hunt CH, et al. AJR 2009;193:1124-1127.
Cochran ST, et al. AJR 2001;176:1385–1388 .Dillman JR, et al. AJR 2008;190:187–190.Dillman JR, et al. AJR 2007;188:1643–1647.Murphy KJ, et al. AJR 1996;167:847–849.ACR. Manual on Contrast Media. Version 6, 2008.
Severe Adverse Events Are Rare
![Page 75: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/75.jpg)
MR CT
NonanaphylactoidReaction
AnaphylactoidReaction
ContrastExtravasation
2005
CIN
![Page 76: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/76.jpg)
Choice of GBCA
• Prior to link with NSF, most radiologists believed that all brands of extracellular GBCAs were very similar in mechanism of action, efficacy and risk of adverse events– Even if they knew about differences in chemical
structure, measure of stability, viscosity,ionicity, etc….. • Purchasing decisions were based primarily on
pricing, GPO contracts, and personal preferences– Magnevist and Omniscan dominated the market
![Page 77: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/77.jpg)
June 8, 2006
There appears to be an association between GBCAs and NSF
![Page 78: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/78.jpg)
May 27, 2007
FDA Boxed WarningMay 27, 2007
![Page 79: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/79.jpg)
Guidelines/Recommendations• FDA• US Professional Organizations
– American College of Radiology• Guidance Document for Safe MR
Practices• Manual on Contrast Media
– National Kidney Foundation• Laminated Reference Tool
– NKF/ACR– Individual Medical Centers and
MRI Facilities• Outside the US
– Europe (EMEA, ESUR)– Canadian Association of
Radiologists– Japan– Australia
Outside of US, all indicate that the risk for NSF varies between types of GBCAs
All recommend screening for renal dysfunction
![Page 80: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/80.jpg)
Use of GBCAs in Clinical Practice• Current Practices: How have they changed since
NSF?– Fewer patients with dialysis and known CKD referred for
GBCA-MRI– Some reluctance to use GBCAs (anecdotal)
• Some MRI facilities no long administer GBCAs• Some MRI facilities will not administer GBCAs to patients with
CKD 3 or any risk factors for CKD (eg. diabetes, hypertension)• Some patients are being “turfed” to other facilities (especially
hospitals)
– Alternative imaging tests (e.g. non-contrast MRI/MRA, low dose contrast-CT)
• Reassessment of the risk of clinically relevant CIN from intravenous iodinated contrast agents
![Page 81: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/81.jpg)
MR CT
NSFCIN
Adverse Events with Contrast Enhanced Imaging
2006
![Page 82: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/82.jpg)
MR CT
NonanaphylactoidReaction
AnaphylactoidReaction
ContrastExtravasation
CIN
NSF
2009
![Page 83: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/83.jpg)
• 40 yo obese f with ADPCKD and eGFR < 30 • Ultrasound showed a 2 cm echogenic mass in the right
kidney• Request imaging to evaluate for renal cell carcinoma
• Volume expansion with saline (hydration)• Premedication with N-acetlycysteine before and after and isotonic sodium
bicarbonate (3cc/kg/hr for 1 hr prior)• Non-C CT
•If fat present in mass, stop (benign AML)•If no fat, perform low dose CE-CT with low-osmolality or iso-osmolality iodinated agent
• CE-MRI with macrocyclic or low dose high relaxivity GBCA
• Diffusion-weighted MRI (no GBCA)
Alternative Imaging Algorithm
![Page 84: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/84.jpg)
• 25 yo m with suspected intramedullary spinal cord tumor• eGFR 28 ml/min/1.73m2 • Request imaging to determine type and extent of mass
• GBCA-enhanced MRI• MRI better that CT • Non-contrast MRI not sufficient
•Use lowest diagnostic dose of macrocyclic or low dose high relaxivity GBCA
Sometimes GBCA-MRI is the best exam, even in patients with compromised renal function !
![Page 85: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/85.jpg)
Use of GBCAs in Clinical Practice• Current Practices: How have they changed
since NSF?– Screening for CKD/risk factors for CKD is much more
common• Enterprise-wide EMR• Require referring MD to provide eGFR or submit CKD
risk factor form prior to scheduling GBCA-MRI• Patient questionnaire prior to exam
– Ranges from one question (“Do you have a problem with your kidneys) to series of questions about risk factors for CKD
• Point-of-service eGFR (based on serum creatinine) in every patient.
Screening results in increased time, costs, and inconvenience
![Page 86: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/86.jpg)
Use of GBCAs in Clinical Practice• Current Practices: How have they changed
since NSF?– Change in GBCA Usage
• Decreased use of linear non-ionic GBCA(s)• “High dose” (>FDA approved dose) MRI/MRA less
common• “Low dose” (< FDA approved dose) MRI more common• Patients with compromised renal function less likely to
get repeat doses of GBCA at short time intervals
![Page 87: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/87.jpg)
Use of GBCAs in Clinical Practice• Current Practices: How have they changed
since NSF?– More common to weigh patient and administer
dose based on patient weight – Documentation of dose and specific GBCA used
![Page 88: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/88.jpg)
Diagnostic/Optimal Dose of GBCA
• Not always known• Depends;
• specific GBCA• patient characteristics• type of MRI exam• MR scanner software/hardware• magnetic field strength
Krautmacher C et al. Radiology. 2005;237:1014-1019.Desai NK, et al Top Magn Reson Imaging 2003;14:360-364Brekenfeld C, et al. Invest Radiol 2001;36:266-275Kuhl CK et al. Radiology. 2008;247:16-35.
![Page 89: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/89.jpg)
Contrast Dose and Field Strength Effects in Contrast Dose and Field Strength Effects in Lesion VisualizationLesion Visualization
•• No significant difference between field strengths for lesions grNo significant difference between field strengths for lesions greater eater than 20 mmthan 20 mm
•• Small lesion visualization at low field strength improves with hSmall lesion visualization at low field strength improves with higher igher contrastcontrast
Low field (0.2T)Single dose
Low field (0.2T)Double dose
Low field (0.2T)Triple dose
High field (1.5T)Single dose
Visualization of metastatic disease in one patient.
Desai NK, et al. Desai NK, et al. Top Top MagnMagn ResonReson ImagingImaging 2003;14:3602003;14:360--364.364.BrekenfeldBrekenfeld C, et al. C, et al. Invest Invest RadiolRadiol. 2001;36:266. 2001;36:266--275.275. Slide courtesy Lawrence Tanenbaum, Mt Sinai
![Page 90: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/90.jpg)
Use of GBCAs in Clinical Practice
• Impact on patients– Questions:
• Are diagnoses being missed?• Are patients receiving suboptimal care because of
concern for NSF?
– Answer• Unknown (has not been studied)
– Concern• In effort to limit risk of NSF, some may be using
suboptimal or non-diagnostic dose in some instances (don’t know what they are missing)
![Page 91: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/91.jpg)
Summary• GBCA-enhanced MRI plays (and will likely
continue to play) an essential role in modern medical diagnosis
• Off-label use (dose and clinical application) is common
• FDA policy and other education efforts have resulted in changes in clinical practice in the United States– Including marked decrease of new cases of NSF
• Effect on patient care?
![Page 92: NSF: History, Diagnosis, and the Registry](https://reader034.fdocuments.us/reader034/viewer/2022052600/557e6b2ed8b42a7b5c8b45fd/html5/thumbnails/92.jpg)
Acknowledgements
• Ali Abu-Alfa: Yale University• Shawn Cowper: Yale University• Philip Kuo: Yale/University of Arizona• Emanual Kanal: University of Pittsburgh• Kenneth Maravilla: University of Washington• Lawrence Tanenbaum: Mount Sinai
• Staff at Yale-New Haven Hospital